- Home
- DYN
as 04-23-2025 4:00pm EST
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
| Founded: | 1984 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 848.8M | IPO Year: | 2020 |
| Target Price: | $47.73 | AVG Volume (30 days): | 2.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.37 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.36 - $47.45 | Next Earning Date: | 05-05-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Dyne Therapeutics Inc. (DYN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Friedl-Naderer Johanna | DYN | Chief Commercial Officer | Mar 13 '25 | Sell | $12.12 | 143 | $1,733.16 | 96,057 | |
| Scalzo Richard William | DYN | SVP, Head of Finance & Admin. | Mar 11 '25 | Sell | $11.38 | 1,343 | $15,283.34 | 122,330 | |
| Beskrovnaya Oxana | DYN | Chief Scientific Officer | Mar 11 '25 | Sell | $11.38 | 2,153 | $24,501.14 | 195,840 | |
| Kerr Douglas | DYN | Chief Medical Officer | Mar 5 '25 | Sell | $11.83 | 1,343 | $15,887.69 | 94,157 | |
| Cox John | DYN | CEO & President | Mar 5 '25 | Sell | $11.83 | 4,061 | $48,041.63 | 146,239 | |
| Scalzo Richard William | DYN | SVP, Head of Finance & Admin. | Mar 5 '25 | Sell | $11.83 | 917 | $10,848.11 | 122,330 | |
| Beskrovnaya Oxana | DYN | Chief Scientific Officer | Mar 5 '25 | Sell | $11.83 | 1,094 | $12,942.02 | 195,840 | |
| Scalzo Richard William | DYN | SVP, Head of Finance & Admin. | Feb 18 '25 | Sell | $13.95 | 2,488 | $34,707.60 | 122,330 | |
| Beskrovnaya Oxana | DYN | Chief Scientific Officer | Feb 18 '25 | Sell | $13.95 | 2,598 | $36,242.10 | 195,840 |
Latest Dyne Therapeutics Inc. News
DYN Breaking Stock News: Dive into DYN Ticker-Specific Updates for Smart Investing
Investor's Business Daily
2 days ago
Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost
GlobeNewswire
9 days ago
Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments
GlobeNewswire
9 days ago
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Simply Wall St.
14 days ago
Insider Purchases Worth US$1.06m See Losses As Dyne Therapeutics Market Value Drops To US$770m
MT Newswires
21 days ago
RBC Cuts Price Target on Dyne Therapeutics to $36 From $41, Keeps Outperform, Speculative Risk
TipRanks
23 days ago
Biotech stocks slide as Marks resignation seen being negative for sector
MT Newswires
a month ago
Sector Update: Health Care Stocks Steady Premarket Friday
MT Newswires
a month ago
Dyne Therapeutics Names Erick Lucera as CFO
Compare DYN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DYN Dyne Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.